Terms: = Prostate cancer AND PR, PGR, progesterone receptor AND Prognosis
49 results:
1. Do Hispanic Puerto Rican men have worse outcomes after radical prostatectomy? Results from SEARCH.
Guerrios-Rivera L; Janes JL; De Hoedt AM; Klaassen Z; Terris MK; Cooperberg MR; Amling CL; Kane CJ; Aronson WJ; Fowke JH; Freedland SJ
Cancer Med; 2024 Feb; 13(4):e7012. PubMed ID: 38457188
[TBL] [Abstract] [Full Text] [Related]
2. Socioeconomic status and cancer survival in Brazil: Analysis of population data from the municipalities of Aracaju and Curitiba, 1996-2012.
Renna Junior NL; Azevedo E Silva G
Cancer Epidemiol; 2023 Aug; 85():102394. PubMed ID: 37419053
[TBL] [Abstract] [Full Text] [Related]
3. The Transcriptomic Profiles of
Olczak M; Orzechowska MJ; Bednarek AK; Lipiński M
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176106
[TBL] [Abstract] [Full Text] [Related]
4. Involvement in Tumorigenesis and Clinical Significance of CXCL1 in Reproductive cancers: Breast cancer, Cervical cancer, Endometrial cancer, Ovarian cancer and prostate cancer.
Korbecki J; Bosiacki M; Barczak K; Łagocka R; Brodowska A; Chlubek D; Baranowska-Bosiacka I
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108425
[TBL] [Abstract] [Full Text] [Related]
5. Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive prostate cancer Treated With Docetaxel Chemotherapy.
Neuberger M; Skladny J; Goly N; Wessels F; WEIß C; Egen L; Erben P; GROß-Weege M; Grüne B; Hartung F; Herrmann J; Honeck P; Jarczyk J; Kowalewski KF; Mühlbauer J; Nitschke K; Nientiedt M; Walach MT; Waldbillig F; Westhoff N; VON Hardenberg J; Kriegmair M; Worst TS; Nuhn P
Anticancer Res; 2022 Apr; 42(4):1911-1918. PubMed ID: 35347010
[TBL] [Abstract] [Full Text] [Related]
6. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite prognosis in prostate cancers.
Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
[TBL] [Abstract] [Full Text] [Related]
7. Clinical and Pathological Features of Prostatic Stromal Tumor of Uncertain Malignant Potential: A Retrospective Study of 23 Chinese Cases.
Shen Q; Zhou Z; Liu Z; Hu S; Lin Z; Li S; Li S; Song H; Chen Y; Meng Y; Wang Y; Fan Y; Li X; Xiao Y; He Q; Jin J; Zhang Q; Yu W
Urol Int; 2021; 105(3-4):206-214. PubMed ID: 33221793
[TBL] [Abstract] [Full Text] [Related]
8. [A clinical analysis of 14 cases of prostatic stromal tumor of uncertain malignant potential].
Liu Y; Liu ZJ; Shen Q; Wu JY; Fan Y; Li DR; Yu W; He ZS
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Aug; 52(4):621-624. PubMed ID: 32773789
[TBL] [Abstract] [Full Text] [Related]
9. Down Regulation of KAI1/CD82 in Lymph Node Positive and Advanced T-Stage Group in Breast cancer Patients.
Krishna Latha T; Verma A; Thakur GK; Banerjee B; Kaur N; Singh UR; Sharma S
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3321-3329. PubMed ID: 31759355
[TBL] [Abstract] [Full Text] [Related]
10. prostate-specific antigen response patterns during cabazitaxel therapy in patients with metastatic castration-resistant prostate cancer.
Kanao K; Ito T; Takahara K; Ando R; Yasui T; Shiroki R; Miyake H; Sumitomo M
Jpn J Clin Oncol; 2019 Dec; 49(11):1043-1048. PubMed ID: 31369101
[TBL] [Abstract] [Full Text] [Related]
11. An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
Miyazawa Y; Sekine Y; Shimizu N; Takezawa Y; Nakamura T; Miyao T; Nakayama H; Kurihara S; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
Prostate; 2019 Sep; 79(12):1462-1470. PubMed ID: 31334872
[TBL] [Abstract] [Full Text] [Related]
12. progesterone receptors in prostate cancer: progesterone receptor B is the isoform associated with disease progression.
Grindstad T; Richardsen E; Andersen S; Skjefstad K; Rakaee Khanehkenari M; Donnem T; Ness N; Nordby Y; Bremnes RM; Al-Saad S; Busund LT
Sci Rep; 2018 Jul; 8(1):11358. PubMed ID: 30054508
[TBL] [Abstract] [Full Text] [Related]
13. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting RhoA-GTP expression.
Jiang J
Biomed Pharmacother; 2017 Oct; 94():439-445. PubMed ID: 28779705
[TBL] [Abstract] [Full Text] [Related]
14. Urinary RKIP/p-RKIP is a potential diagnostic and prognostic marker of clear cell renal cell carcinoma.
Papale M; Vocino G; Lucarelli G; Rutigliano M; Gigante M; Rocchetti MT; Pesce F; Sanguedolce F; Bufo P; Battaglia M; Stallone G; Grandaliano G; Carrieri G; Gesualdo L; Ranieri E
Oncotarget; 2017 Jun; 8(25):40412-40424. PubMed ID: 28418894
[TBL] [Abstract] [Full Text] [Related]
15. Abiraterone Acetate for Metastatic prostate cancer in Patients With Suboptimal Biochemical Response to Hormone Induction.
Flaig TW; Plets M; Hussain MHA; Agarwal N; Mitsiades N; Deshpande HA; Vaishampayan UN; Thompson IM
JAMA Oncol; 2017 Nov; 3(11):e170231. PubMed ID: 28358937
[TBL] [Abstract] [Full Text] [Related]
16. Mechanism of paclitaxel resistance in a human prostate cancer cell line, PC3-PR, and its sensitization by cabazitaxel.
Sobue S; Mizutani N; Aoyama Y; Kawamoto Y; Suzuki M; Nozawa Y; Ichihara M; Murate T
Biochem Biophys Res Commun; 2016 Oct; 479(4):808-813. PubMed ID: 27687545
[TBL] [Abstract] [Full Text] [Related]
17. A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial.
Falk RT; Staff AC; Bradwin G; Karumanchi SA; Troisi R
Cancer Causes Control; 2016 Aug; 27(8):1009-17. PubMed ID: 27357932
[TBL] [Abstract] [Full Text] [Related]
18. progesterone receptor modulates ERα action in breast cancer.
Mohammed H; Russell IA; Stark R; Rueda OM; Hickey TE; Tarulli GA; Serandour AA; Birrell SN; Bruna A; Saadi A; Menon S; Hadfield J; Pugh M; Raj GV; Brown GD; D'Santos C; Robinson JL; Silva G; Launchbury R; Perou CM; Stingl J; Caldas C; Tilley WD; Carroll JS
Nature; 2015 Jul; 523(7560):313-7. PubMed ID: 26153859
[TBL] [Abstract] [Full Text] [Related]
19. The anti-androgen drug dutasteride renders triple negative breast cancer cells more sensitive to chemotherapy via inhibition of HIF-1α-/VEGF-signaling.
von Wahlde MK; Hülsewig C; Ruckert C; Götte M; Kiesel L; Bernemann C
Gynecol Endocrinol; 2015 Feb; 31(2):160-4. PubMed ID: 25356777
[TBL] [Abstract] [Full Text] [Related]
20. Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.
Harouaka R; Kang Z; Zheng SY; Cao L
Pharmacol Ther; 2014 Feb; 141(2):209-21. PubMed ID: 24134902
[TBL] [Abstract] [Full Text] [Related]
[Next]
